Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

NCT03896646 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03896646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03896646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 10, 2019
Completion date
September 30, 2026
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii hepatocellular carcinoma ajcc v8, stage iiia hepatocellular carcinoma ajcc v8, stage iiib hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, unresectable hepatocellular carcinoma